alexa Radiation Maculopathy Treated with Ranibizumab
ISSN: 2155-9570

Journal of Clinical & Experimental Ophthalmology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

Radiation Maculopathy Treated with Ranibizumab

Alex Yuan and Rishi P. Singh*
Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA
Corresponding Author : P. Singh
Cole Eye Institute, Cleveland Clinic
9500 Euclid Ave i31, Cleveland, OH, 44195, USA
Tel: 216-445-9497
E-mail: [email protected]
Received December 23, 2010; Accepted February 09, 2011; Published February 11, 2011
Citation: Yuan A, Singh RP (2011) Radiation Maculopathy Treated with Ranibizumab. J Clinic Experiment Ophthalmol 2:129. doi:10.4172/2155-9570.1000129
Copyright: © 2011 Yuan A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google
 

Abstract

Aim: Radiation maculopathy is a major cause of vision loss after brachytherapy or localized radiation treatments. Here, we describe a case report of a patient with bilateral radiation maculopathy and macular edema treated with ranibizumab and panretinal laser photocoagulation.
 
Methods: Baseline fluorescein angiography and spectral domain OCT (SDOCT) was obtained. Eight-monthly intravitreous injections of ranibizumab 0.5 mg were performed in each eye. Snellen visual acuity, central subfield thickness (CST), total cube volume (TCV), cube average thickness (CAT) was recorded and a fundoscopic exam was performed at each visit. A final fluorescein angiography was obtained at the final visit.
 
Results:
After 8 treatments of ranibizumab 0.5 mg, Snellen visual acuity was 20/200 OD and 20/40 OS. The final CST was 392 µm OD and 495 µm OS, TCV was 13.4 mm3 OD and 11.1 mm3 OS, and CAT was 371 µm OD and 310 µm OS. Fundus photography and fluorescein angiography showed stabilization of radiation maculopathy OU but prominent macular ischemia OD.
 
Conclusion: Vision loss from radiation maculopathy can be successfully treated with off-label ranibizumab in the short term. However, visual improvement is limited by macular ischemia, which had a larger effect on final visual acuity than reductions in CST, TCV, or CAT. Our study and others suggest that larger clinical trials to determine the dose, timing, and duration of ranibizumab treatment could benefit patients with radiation maculopathy.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords